Rigel Pharmaceuticals RIGL EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Rigel Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's EBITDA margin?
- Rigel Pharmaceuticals (RIGL) reported EBITDA margin of 42.4% in Q1 2026.
- How has Rigel Pharmaceuticals's EBITDA margin changed year-over-year?
- Rigel Pharmaceuticals's EBITDA margin increased by 85.5% year-over-year, from 22.8% to 42.4%.
- What is the long-term trend for Rigel Pharmaceuticals's EBITDA margin?
- Over 5 years (2020 to 2025), Rigel Pharmaceuticals's EBITDA margin has grown at a 10.8% compound annual growth rate (CAGR), from -26% to 43.5%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.